

Characterization of [¹¹C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain

Authors: Kai-Chun Yang¹, Vladimir Stepanov¹, Nahid Amini¹, Stefan Martinsson¹, Akihiro Takano¹, Jacob Nielsen², Christoffer Bundgaard³, Benny Bang-Andersen³, Sarah Grimwood⁴, Christer Halldin¹, Lars Farde^{1, 5}, Sjoerd J. Finnema^{1, #}

Affiliations: ¹ Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; ² Synaptic Transmission, H. Lundbeck A/S, Valby, Denmark; ³ Discovery Chemistry and DMPK, H. Lundbeck A/S, Valby, Denmark; ⁴ Neuroscience and Pain Research Unit, Pfizer Inc., Cambridge, MA, USA; ⁵ Personalized Health Care and Biomarkers, AstraZeneca PET Science Center at Karolinska Institutet, Stockholm, Sweden

[#]current affiliation: Yale University, Department of Radiology and Biomedical Imaging, New Haven, CT, USA

Address of Corresponding author: Kai-Chun Yang, Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Karolinska University Hospital, Building R5:02, SE-17176 Stockholm, Sweden. Tel. Nr: +46-8-51772997, Fax. Nr: +46-8-51771753, Email: kai-chun.yang@ki.se

SUPPLEMENTAL RESULTS


FIGURE LEGENDS

Fig. S1 Plasma concentration of pretreatment drugs in cynomolgus monkeys. (a) MP-10 1.5mg/kg in NHP1 (b) MP-10 1.5mg/kg in NHP2 (c) Lu AE92686 0.5 mg/kg (d) Lu AE92686 2.0 mg/kg


Fig. S2 Plasma fraction of unchanged [^{11}C]Lu AE92686 over time for baseline and pretreatment experiments. (a) MP-10 1.5mg/kg in NHP1 (b) MP-10 1.5mg/kg in NHP2 (c) Lu AE92686 0.5 mg/kg (d) Lu AE92686 2.0 mg/kg

Fig. S1


a MP-10 1.5 mg/kg (NHP1)



b MP-10 1.5mg/kg (NHP2)



c Lu AE92686 0.5 mg/kg



d Lu AE92686 2.0 mg/kg






Fig. S2


a MP-10 1.5 mg/kg (NHP1)



b MP-10 1.5mg/kg (NHP2)



c Lu AE92686 0.5 mg/kg



d Lu AE92686 2.0 mg/kg

